Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-131461 in Patients Hospitalized for Worsening Heart Failure
NCT06795399Phase 2Withdrawn
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Apr 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of OPC-131461 in heart failure (HF) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Proportional Change From Baseline in Serum Concentration of NT-proBNP at Day 31. Planned start Apr 2025; status: withdrawn.
02
Drugs
OPC-131461
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06795399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795399.